https://www.selleckchem.com/pr....oducts/pf-477736.htm
Background and Aims Glecaprevir/pibrentasvir is a pangenotypic regimen recently approved for the treatment of chronic hepatitis C virus (HCV) infection. The objective of the present review was to summarize the findings from clinical trials to understand how patient-related factors influence glecaprevir/pibrentasvir efficacy (sustained virologic response rates at 12 weeks' after treatment [referred to as SVR12]) and safety. Methods Data from 21 phase III clinical trials were analyzed. Results The integrated efficacy analysis included 4
Like
Comment
Share
